Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...